FDA Vectibix Review Posits Study Design Issues That Could Have Led To Lack Of Survival Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Review documents for the biologic show disagreement between statistical and medical reviewers over utility of progression-free survival in predicting an overall survival benefit.